X0508 4 2026-03-06 0001368514 ADMA BIOLOGICS, INC. ADMA 0002017423 Kestenberg-Messina Kaitlin M. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON FL 33487 true COO and SVP, Compliance false Common Stock 2026-03-06 4 F 0 10059 15.39 D 562101 D Common Stock 2026-03-07 4 F 0 4235 15.39 D 557866 D Common Stock 2026-03-09 4 J 0 91266 0 D 466600 D Common Stock 2026-03-09 4 M 0 2500 5 A 469100 D Common Stock 2026-03-09 4 M 0 1250 4.31 A 470350 D Common Stock 2026-03-09 4 M 0 2646 2.83 A 472996 D Common Stock 2026-03-09 4 M 0 1525 2.35 A 474521 D Common Stock 2026-03-09 4 M 0 2175 1.55 A 476696 D Common Stock 2026-03-09 4 S 0 10096 15.63 D 466600 D Stock Option (right to buy) 5 2026-03-09 4 M 0 2500 0 D 2027-02-14 Common Stock 2500 2500 D Stock Option (right to buy) 4.31 2026-03-09 4 M 0 1250 0 D 2029-06-05 Common Stock 1250 1250 D Stock Option (right to buy) 2.83 2026-03-09 4 M 0 2646 0 D 2030-08-19 Common Stock 2646 2771 D Stock Option (right to buy) 2.35 2026-03-09 4 M 0 1525 0 D 2031-02-25 Common Stock 1525 2225 D Stock Option (right to buy) 1.55 2026-03-09 4 M 0 2175 0 D 2031-07-19 Common Stock 2175 2825 D Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement"). The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested. The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested. The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested. The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested. The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested. /s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact 2026-03-10